ATE267601T1 - Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure - Google Patents

Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure

Info

Publication number
ATE267601T1
ATE267601T1 AT01906523T AT01906523T ATE267601T1 AT E267601 T1 ATE267601 T1 AT E267601T1 AT 01906523 T AT01906523 T AT 01906523T AT 01906523 T AT01906523 T AT 01906523T AT E267601 T1 ATE267601 T1 AT E267601T1
Authority
AT
Austria
Prior art keywords
monothioglycerol
cysteine
pharmaceutical composition
composition containing
thioglycolic acid
Prior art date
Application number
AT01906523T
Other languages
English (en)
Inventor
Jens Kemken
Bernd Ulrich Riebesehl
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002691A external-priority patent/GB2358799A/en
Priority claimed from GB0019599A external-priority patent/GB2365768A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE267601T1 publication Critical patent/ATE267601T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01906523T 2000-02-04 2001-01-23 Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure ATE267601T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002691A GB2358799A (en) 2000-02-04 2000-02-04 A pharmaceutical composition comprising pemetrexed and an antioxidant
GB0019599A GB2365768A (en) 2000-08-09 2000-08-09 Stable liquid composition containing pemetrexed
PCT/US2001/000648 WO2001056575A1 (en) 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid

Publications (1)

Publication Number Publication Date
ATE267601T1 true ATE267601T1 (de) 2004-06-15

Family

ID=26243579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01906523T ATE267601T1 (de) 2000-02-04 2001-01-23 Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure

Country Status (30)

Country Link
EP (1) EP1265612B1 (de)
JP (1) JP2003521518A (de)
KR (1) KR20020081293A (de)
CN (1) CN1396828A (de)
AR (1) AR027360A1 (de)
AT (1) ATE267601T1 (de)
AU (1) AU3442201A (de)
BR (1) BR0107958A (de)
CA (1) CA2399124A1 (de)
CO (1) CO5280222A1 (de)
CZ (1) CZ20022654A3 (de)
DE (1) DE60103512T2 (de)
DK (1) DK1265612T3 (de)
DZ (1) DZ3269A1 (de)
EA (1) EA004708B1 (de)
ES (1) ES2220716T3 (de)
HR (1) HRP20020636A2 (de)
HU (1) HUP0300709A3 (de)
IL (1) IL150475A0 (de)
MX (1) MXPA02007191A (de)
MY (1) MY129450A (de)
NO (1) NO20023379L (de)
NZ (1) NZ519727A (de)
PE (1) PE20011223A1 (de)
PL (1) PL356705A1 (de)
PT (1) PT1265612E (de)
SK (1) SK10982002A3 (de)
SV (1) SV2002000301A (de)
TR (1) TR200401436T4 (de)
WO (1) WO2001056575A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232271D1 (de) * 2001-12-28 2009-06-18 Eisai Corp North America Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (de) 2012-05-21 2013-11-27 Synthon BV Stabilisierte Flüssigkeitszusammensetzung mit Pemetrexed
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101260636B1 (ko) * 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
CN103340826B (zh) * 2013-07-05 2015-09-09 浙江震元制药有限公司 美他多辛注射用组合物及其制备方法
CN105611932B (zh) * 2013-10-03 2019-02-12 富士胶片株式会社 注射液制剂及其制造方法
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
ES2686870T3 (es) * 2014-03-28 2018-10-22 Fujifilm Corporation Preparación de inyección y método para producirla
WO2016024369A1 (ja) * 2014-08-13 2016-02-18 テバ製薬株式会社 がん治療用医薬組成物
EA034559B1 (ru) 2014-10-16 2020-02-20 Синтон Б.В. Жидкая фармацевтическая композиция, содержащая пеметрексед
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP2019094284A (ja) * 2017-11-21 2019-06-20 日本化薬株式会社 ペメトレキセドを含有する注射用溶液製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체

Also Published As

Publication number Publication date
JP2003521518A (ja) 2003-07-15
HUP0300709A3 (en) 2005-04-28
PT1265612E (pt) 2004-08-31
EP1265612A1 (de) 2002-12-18
MXPA02007191A (es) 2002-12-09
AU3442201A (en) 2001-08-14
CO5280222A1 (es) 2003-05-30
NO20023379L (no) 2002-09-30
CZ20022654A3 (cs) 2003-01-15
CA2399124A1 (en) 2001-08-09
ES2220716T3 (es) 2004-12-16
SV2002000301A (es) 2002-06-07
BR0107958A (pt) 2002-10-29
CN1396828A (zh) 2003-02-12
HRP20020636A2 (en) 2003-10-31
PL356705A1 (en) 2004-06-28
PE20011223A1 (es) 2001-12-20
KR20020081293A (ko) 2002-10-26
HUP0300709A2 (hu) 2003-07-28
DZ3269A1 (fr) 2001-08-09
DE60103512T2 (de) 2005-06-02
NZ519727A (en) 2004-04-30
EA200200831A1 (ru) 2003-02-27
AR027360A1 (es) 2003-03-26
DK1265612T3 (da) 2004-08-09
DE60103512D1 (de) 2004-07-01
HK1052461A1 (en) 2003-09-19
MY129450A (en) 2007-04-30
NO20023379D0 (no) 2002-07-12
WO2001056575A1 (en) 2001-08-09
EP1265612B1 (de) 2004-05-26
EA004708B1 (ru) 2004-06-24
TR200401436T4 (tr) 2004-07-21
SK10982002A3 (sk) 2003-03-04
IL150475A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
ATE267601T1 (de) Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l- cystein oder thioglykolsäure
PL363215A1 (pl) Kompozycja farmaceutyczna o zmniejszonej tendencji do krystalizacji leku
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
DE60209785D1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
DE60209145D1 (de) Pharmazeutische formulierungen mit platinderivaten
DE60127002D1 (de) Pharmazeutische zusammensetzung
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
DE60118008D1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
ATE324882T1 (de) In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit agomelatin
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
DE60129238D1 (de) Pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE602005021475D1 (de) Magenresistente pharmazeutische dosierform mit n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutaminsäure (lk-423)
ATE412405T1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60212728D1 (de) Stabile pharmazeutische zusammensetzung mit erythropoietin
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
UEP Publication of translation of european patent specification

Ref document number: 1265612

Country of ref document: EP